Abstract
Z anamivir [‘Relenza’] is an exciting new neuraminidase inhibitor indicated for the treatment of influenza virus infection, New data presented at the 21st International Congress on Chemotherapy [ Birmingham, UK; July 1999 ] suggest that zanamivir’s clinical benefits have implications for the economic burden of influenza. It appears that, by preventing influenza, zanamivir avoids the lost productivity associated with the disease.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Innes, C. Zanamivir. Pharmacoecon. Outcomes News 228, 3–4 (1999). https://doi.org/10.1007/BF03275071
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275071